Chewable Tablet Adverse Events, Manufacturing Slips Prompt FDA Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Chewable tablet manufacturers are overlooking quality attributes, leading to adverse events, according to an FDA draft guidance. The agency recommends firms establish hardness, dissolution and disintegration of products early in manufacturing.